๐ŸŒ Clinical Trials – An Overview

By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD 

๐Ÿ”น What Are Clinical Trials?

A clinical trial is a scientifically controlled, ethically approved study in human participants designed to evaluate a new drug’s:

  • Safety

  • Efficacy

  • Tolerability

  • Optimal dosage

๐Ÿ‘‰ Clinical trials are mandatory after preclinical testing in animals.
They require prior approval from regulatory authorities:

  • DCGI (India)

  • FDA (USA)

  • EMA (Europe)

Permission to begin human studies is granted through an Investigational New Drug (IND) application, which includes preclinical safety data, manufacturing details, and trial protocols.


๐Ÿ”น Ethical Principles in Clinical Trials

All trials must follow bioethics principles to protect human subjects:

PrincipleMeaning
AutonomyRespect participants’ right to make informed decisions
BeneficenceMaximize potential benefits
Non-maleficence“Do no harm” – minimize risks
JusticeEnsure fair participant selection and equitable distribution of risks/benefits

Ethics Committee (IEC/IRB) approval is mandatory before starting a trial.

In India, Clinical Trial Registry of India (CTRI) registration is mandatory before starting any human clinical trial.

๐Ÿ”น Clinical Trial Registration in India

  • In India, registration of all clinical trials in the CTRI (Clinical Trial Registry – India) is mandatory.

  • CTRI is a free, online public record system under the ICMR (Indian Council of Medical Research) and the National Institute of Medical Statistics (NIMS).

  • Since June 15, 2009, the DCGI (Drug Controller General of India) has made CTRI registration compulsory for:

    • Regulatory drug trials (new drugs, biologics, vaccines)

    • Academic / investigator-initiated trials

    • Interventional trials (devices, procedures, AYUSH interventions)

  • Even post-marketing surveillance trials and bioequivalence studies must be registered.

Why CTRI Registration Matters

  1. Transparency – makes trial details publicly accessible.

  2. Ethical Compliance – aligns with ICMR guidelines & Declaration of Helsinki.

  3. Avoids duplication – prevents unnecessary repetition of similar trials.

  4. Publication requirement – leading journals (ICMJE, PubMed indexed) demand trial registration number (CTRI/XXXX/XX/XXXX).

  5. Regulatory Oversight – helps DCGI and Ethics Committees monitor trial status.


๐Ÿ‘‰ So the regulatory flow in India is:
Preclinical → DCGI approval (IND) → Ethics Committee approval → CTRI Registration → Trial initiation.


๐Ÿ”น Phases of Clinical Trials

Phase 0 (Microdosing Studies)Exploratory

  • Participants: 6–15 volunteers/patients

  • Dose: Sub-therapeutic (<1/100th active dose)

  • Objective: Study PK/PD and target engagement (not efficacy)

  • Outcome: Early “go/no-go” decision to save cost and risk

  • Tools: AMS, PET imaging, biomarker analysis

Example: Using microdose PET imaging of a new anticancer drug to see if it reaches tumor tissue.


Phase I (Human Safety & Dosage)

  • Participants: 10–100 healthy volunteers (or patients in oncology trials)

  • Objective: Safety, tolerability, maximum tolerated dose (MTD), PK/PD data

  • Design: Open-label, non-randomized

  • Setting: Research units with close monitoring


Phase II (Therapeutic Exploration)

  • Participants: 50–500 patients with the target disease

  • Objective: Explore efficacy, define dose range, continue PK/PD + safety evaluation

  • Design: Randomized, controlled, often single-blind

  • Setting: Conducted in a few (3–4) medical centers


Phase III (Therapeutic Confirmation)

  • Participants: 1,000–5,000+ diverse patients

  • Objective: Confirm efficacy, detect uncommon ADRs, study interactions, long-term safety

  • Design: Multicenter, randomized, double-blind, comparative

  • Outcome: If successful → regulatory approval & marketing license

Gold standard for evidence-based medicine.


Phase IV (Postmarketing Surveillance)

  • Conducted after approval

  • Objective: Detect rare/long-term ADRs, study real-world effectiveness, evaluate in special populations (children, elderly, pregnancy)

  • Methods: Cohort studies, registries, spontaneous ADR reporting

  • Legal Requirement: Manufacturers must submit Periodic Safety Update Reports (PSURs) to DCGI/CDSCO.


๐Ÿ”น Other Clinical Research Designs (Beyond RCTs)

Study TypePurpose
Case–ControlRetrospective, compare diseased vs non-diseased
CohortProspective, follow exposed vs unexposed
Meta-analysisPool multiple studies for stronger conclusions

๐Ÿ”น Why Is This Important?

  • Trials are the bridge between lab research and real-world medicine.

  • Builds foundation for rational, ethical prescribing.

  • Future doctors may:

    • Recruit patients into trials

    • Monitor ADRs/SAEs

    • Interpret trial data for practice

  • Encourages awareness of regulatory science & pharmacovigilance.


๐Ÿ“ Summary Table

PhaseParticipantsKey FocusDesignOutcome
06–15PK/PD at microdoseExploratory, non-therapeuticEarly go/no-go
I10–100Safety, tolerability, PK/PDOpen-labelMTD & safe dose
II50–500Efficacy, dose-responseRandomized, single-blindProof of concept
III1000–5000+Confirm efficacy, ADRsRCT, double-blind, multicenterRegulatory approval
IVPost-approvalRare ADRs, real-world dataObservational, PSURsLong-term safety


๐Ÿ“˜ Prepared by Dr. Sk Sabir Rahaman
๐Ÿ“ Specialist Family Physician | Consultant Pharmacologist | Lifestyle & Diabetes Expert

๐ŸŒ Visit My Website for  Articles & other Free PDFs and Resources

Comments

Popular posts from this blog

๐Ÿฅ Insulin Storage: Myths vs. Facts Every Diabetic Should Know

๐Ÿงด TREATMENT OF POISONING – A COMPREHENSIVE OVERVIEW

๐ŸŒฟ Rational Use of Medicines (RUM): A Guide for Safer and Smarter Prescribing